Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.31 |
| ▸ | KDM4A | O75164 | 1/20 | 0.31 |
| ▸ | KDM4B | O94953 | 1/20 | 0.31 |
| ▸ | KDM5C | P41229 | 1/20 | 0.31 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.31 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.31 |
| ▸ | KDM3A | Q9Y4C1 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL170132 | 0.72 | ACVR1 (0.43) | ACVR1KDM4AKDM4BKDM5CKDM5B | |
| SCHEMBL4948959 | 0.70 | — | — | |
| SCHEMBL4052150 | 0.65 | NR1H2 (0.36) | ALDH1A1ACVR1 | |
| SCHEMBL12406064 | 0.65 | PARP1 (0.35) | ALDH1A1ACVR1 | |
| SCHEMBL21199524 | 0.65 | PARP1 (0.35) | — | |
| SCHEMBL12102064 | 0.65 | TNKS2 (0.36) | — | |
| Hydrochloric Acid SCHEMBL17868497 | 0.64 | PARP1 (0.34) | ALDH1A1 | |
| SCHEMBL13218216 | 0.63 | ALDH1A1 (0.36) | ALDH1A1KDM4AKDM4BKDM5CKDM4C | |
| SCHEMBL16663842 | 0.62 | ACVR1 (0.51) | ACVR1KDM5B | |
| SCHEMBL18956248 | 0.62 | NR1H2 (0.36) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 141 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2807163-A1 | PDE9 INHIBITORS WITH IMIDAZO TRIAZINONE BACKBONE | H. Lundbeck A/S (DK) | 2014-12-03 | — | — | EP | claimed |
| WO-2013110768-A1 | PDE9 INHIBITORS WITH IMIDAZO TRIAZINONE BACKBONE | H. LUNDBECK A/S (DK) | 2013-08-01 | — | — | WO | claimed |
| US-20260001885-A1 | 4-IMIDAZOPYRIDAZIN-1-YL-BENZAMIDES AS BTK INHIBITORS | MERCK SHARP & DOHME (NL) | 2026-01-01 | — | — | US | disclosed |
| US-20250360137-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | FREEDOM BIOSCIENCES INC (US) | 2025-11-27 | — | — | US | disclosed |
| US-20250276983-A1 | COMPOUNDS AND METHODS FOR MODULATING HER2 | IAMBIC THERAPEUTICS, INC. | 2025-09-04 | — | — | US | disclosed |
| EP-4577549-A1 | COMPOUNDS AND METHODS FOR MODULATING HER2 | Iambic Therapeutics, Inc. (US) | 2025-07-02 | — | — | EP | disclosed |
| US-12162890-B2 | Heteroaromatic NMDA receptor modulators and uses thereof | NOVARTIS AG (CH) | 2024-12-10 | — | — | US | disclosed |
| US-12152051-B2 | Cyclic dinucleotide analogue, pharmaceutical composition thereof, and application | Shanghai De Novo Pharmatech Co., Ltd. (CN) | 2024-11-26 | — | — | US | disclosed |
| US-12145948-B2 | Compounds and methods for modulating HER2 | IAMBIC THERAPEUTICS, INC. (US) | 2024-11-19 | — | — | US | disclosed |
| EP-3854799-B1 | CYCLIC DINUCLEOTIDE ANALOGUE, PHARMACEUTICAL COMPOSITION THEREOF, AND APPLICATION | SHANGHAI DE NOVO PHARMATECH CO LTD (CN) | 2024-07-17 | — | — | EP | disclosed |
| EP-3854799-B1 | CYCLIC DINUCLEOTIDE ANALOGUE, PHARMACEUTICAL COMPOSITION THEREOF, AND APPLICATION | SHANGHAI DE NOVO PHARMATECH CO LTD (CN) | 2024-07-17 | — | — | EP | disclosed |
| WO-2008117169-A1 | PYRIMIDO [4, 5-D] AZEPINE DERIVATIVES AS 5-HT2C AGONISTS | PFIZER LIMITED (GB) | 2008-10-02 | — | — | WO | disclosed |
| US-20080167462-A1 | 2-substituted phenyl-5, 7-dehydrocarbyl-3, 7-dihydropyrrolo [2, 3-d] pyrimidin-4-one derivatives, the preparation and the pharmaceutical use thereof | TIANJIN TASLY GROUP CO., LTD (CN) | 2008-07-10 | — | — | US | disclosed |
| US-20060264624-A1 | Methods for synthesizing imidazotriazinones | LEXICON GENETICS INCORPORATED | 2006-11-23 | — | — | US | disclosed |
| US-20060173025-A1 | 2-Substituted phenyl-5,7-dialkyl-3,7-dihydropyrrole [2,3-d]pyrimidine-4-one derivatives, the preparation and the pharmaceutical use thereof | YANGTZE RIVER PHARMACEUTICAL (GROUP) CO., LTD. (CN) | 2006-08-03 | — | — | US | disclosed |
| EP-1634883-A1 | 2-SUBSTITUTED PHENYL-5,7-DIALKYL-3,7-DIHYDROPYRROLE[2,3-D]PYRIMIDINE-4-ONE DERIVATIVES, THE PREPARATION AND THE PHARMACEUTICAL USE THEREOF | Tianjin Tasly Group Co., Ltd. (CN) | 2006-03-15 | — | — | EP | disclosed |
| EP-1392314-A1 | NOVEL USE OF 2-PHENYL-SUBSTITUTED IMIDAZOTRIAZINONES | Bayer HealthCare AG (DE) | 2004-03-03 | — | — | EP | disclosed |
| WO-2002089808-A1 | NOVEL USE OF 2-PHENYL-SUBSTITUTED IMIDAZOTRIAZINONES | BAYER HEALTHCARE AG (DE) | 2002-11-14 | — | — | WO | disclosed |
| US-4308384-A | Production of triazinones | GLAXO GROUP LIMITED (GB) | 1981-12-29 | — | — | US | disclosed |
| EP-0009384-A1 | Processes for the preparation of triazinones and condensed triazinones, and compounds so obtained | GLAXO GROUP LIMITED (GB) | 1980-04-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080167462-A1 | 2-substituted phenyl-5, 7-dehydrocarbyl-3, 7-dihydropyrrolo [2, 3-d] pyrimidin-4-one derivatives, the preparation and the pharmaceutical use thereof | PDE5A, PDE3B, PDE2A | ALDH1A1 681/4885ACVR1 2903/4885KDM4A 2303/4885 |
| US-12162890-B2 | Heteroaromatic NMDA receptor modulators and uses thereof | GRIN2C, GRIN2A, GRIN1 | ALDH1A1 1771/4885ACVR1 3993/4885KDM4A 2100/4885 |
| US-20060173025-A1 | 2-Substituted phenyl-5,7-dialkyl-3,7-dihydropyrrole [2,3-d]pyrimidine-4-one derivatives, the preparation and the pharmaceutical use thereof | PDE5A, PDE3B, PDE2A | ALDH1A1 1203/4885ACVR1 2865/4885KDM4A 2103/4885 |
| US-20250360137-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | PDE9A, PDE3A, PDE2A | ALDH1A1 1406/4885ACVR1 3984/4885KDM4A 1035/4885 |
| US-12145948-B2 | Compounds and methods for modulating HER2 | ERBB2, EGFR, ERBB3 | ALDH1A1 2783/4885ACVR1 2502/4885KDM4A 3289/4885 |
| US-12152051-B2 | Cyclic dinucleotide analogue, pharmaceutical composition thereof, and application | STING1, CGAS, IRF3 | ALDH1A1 4772/4885ACVR1 1890/4885KDM4A 3989/4885 |
| US-20260001885-A1 | 4-IMIDAZOPYRIDAZIN-1-YL-BENZAMIDES AS BTK INHIBITORS | BTK, ABL1, FLT3 | ALDH1A1 4166/4885ACVR1 4661/4885KDM4A 982/4885 |
| US-20250276983-A1 | COMPOUNDS AND METHODS FOR MODULATING HER2 | ERBB2, EGFR, ERBB3 | ALDH1A1 2783/4885ACVR1 2502/4885KDM4A 3289/4885 |
| US-20060264624-A1 | Methods for synthesizing imidazotriazinones | PDE3A, PDE2A, PDE3B | ALDH1A1 1422/4885ACVR1 1238/4885KDM4A 270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.